A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension (PAH), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies. As a public benefit corporation (PBC), we aim to deliver meaningful impacts for our patients, our people, our shareholders, and other stakeholders. Our public benefit purpose, as outlined in our charter and approved by our shareholders, is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 3.2B | 3.2B | 2.9B | 2.3B | 1.9B | 1.7B |
| Net Income | 1.3B | 1.3B | 1.2B | 985M | 727M | 476M |
| EPS | $27.86 | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 |
| Free Cash Flow | 1.0B | 1.0B | 1.1B | 748M | 664M | 477M |
| ROIC | 21.0% | 31.6% | 31.6% | 25.6% | 20.9% | 13.1% |
| Gross Margin | 87.9% | 87.9% | 89.2% | 88.9% | 70.1% | 71.3% |
| Debt/Equity | 0.00 | 0.11 | 0.00 | 0.10 | 0.33 | 0.40 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 1.5B | 1.5B | 1.4B | 1.2B | 980M | 556M |
| Operating Margin | 46.9% | 46.9% | 47.9% | 50.9% | 50.6% | 33.0% |
| ROE | 18.8% | 19.7% | 19.2% | 18.3% | 16.6% | 12.9% |
| Shares Outstanding | 48M | 48M | 49M | 50M | 48M | 47M |
UNITED THERAPEUTICS Corp passes 7 of 9 quality checks, indicating strong fundamentals.
UNITED THERAPEUTICS Corp trades at 20.7x trailing earnings, compared to its 15-year median P/E of 14.6x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 24.3x vs a median of 16.2x. The company's 5-year average ROIC is 24.6% with a gross margin of 81.5%. Total shareholder yield (buybacks) is 3.6%. At current prices, the estimated annualized return to fair value is +20.0%.
UNITED THERAPEUTICS Corp (UTHR) has a current P/E ratio of 20.7, compared to its historical median P/E of 14.6. The stock is currently considered Expensive based on its historical valuation range.
UNITED THERAPEUTICS Corp (UTHR) has a 5-year average return on invested capital (ROIC) of 24.6%. This indicates strong capital allocation and a potential competitive advantage.
UNITED THERAPEUTICS Corp (UTHR) has a market capitalization of $27.7B. It is classified as a large-cap stock.
UNITED THERAPEUTICS Corp (UTHR) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 3.61%.
Based on historical P/E analysis, UNITED THERAPEUTICS Corp (UTHR) appears expensive. The current P/E of 20.7 is 42% above its historical median of 14.6. The estimated fair value CAGR (P/E method) is 28.9%.
UNITED THERAPEUTICS Corp (UTHR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
UNITED THERAPEUTICS Corp (UTHR) reported annual revenue of $3.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
UNITED THERAPEUTICS Corp (UTHR) has a net profit margin of 41.9%. This is a strong margin indicating high profitability.
UNITED THERAPEUTICS Corp (UTHR) generated $1.0 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
UNITED THERAPEUTICS Corp (UTHR) has a debt-to-equity ratio of 0.11. This indicates a conservatively financed balance sheet.
UNITED THERAPEUTICS Corp (UTHR) reported earnings per share (EPS) of $27.86 in its most recent fiscal year.
UNITED THERAPEUTICS Corp (UTHR) has a return on equity (ROE) of 19.7%. This indicates the company generates strong returns for shareholders.
UNITED THERAPEUTICS Corp (UTHR) has a 5-year average gross margin of 81.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for UNITED THERAPEUTICS Corp (UTHR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
UNITED THERAPEUTICS Corp (UTHR) has a book value per share of $148.12, based on its most recent annual SEC filing.